Skip to main navigation

Now accepting applications for SPARK™ - Albireo’s Grants in Rare Liver Disease program. Learn more.

Clinical Trials
Partnerships
Media
Careers
Contact

Science & Medicine
Patients & Families
Responsibility
About Us
- Leadership
- Board of Directors
Investors

+

Science & Medicine
Patients & Families
Responsibility
About Us
Investors
Careers
Media
Contact

Press Releases

Year

July 6, 2022

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

June 30, 2022

Albireo to Present at the William Blair Biotech Focus Conference 2022

June 24, 2022

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

June 23, 2022

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

June 8, 2022

Albireo to Present New Data at the EASL International Liver Congress™ 2022

June 7, 2022

Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

June 2, 2022

Albireo to Participate at Upcoming Investor Conferences

May 23, 2022

Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022

May 19, 2022

Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022

May 9, 2022

Albireo to Report Q1 2022 Financial Results on May 16

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Email Alerts
RSS
Print

Site Map
Privacy Policy
Terms of Use
Cookie Settings
Contact

© 2022 Albireo Pharma, Inc